ALK2 inhibitors display beneficial effects in preclinical models of


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
2019
Historique:
received: 05 03 2019
accepted: 08 04 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 18 5 2019
Statut: epublish

Résumé

Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in

Identifiants

pubmed: 31098401
doi: 10.1038/s42003-019-0420-8
pii: 420
pmc: PMC6509210
doi:

Substances chimiques

Antineoplastic Agents 0
LDN 193189 0
Protein Kinase Inhibitors 0
Pyrazoles 0
Pyridines 0
Pyrimidines 0
ACVR1 protein, human EC 2.7.11.30
Activin Receptors, Type I EC 2.7.11.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

156

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C13468/A14078
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106169/ZZ14/Z
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

J Neurooncol. 2017 Apr;132(2):255-266
pubmed: 28110411
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Nat Med. 2017 Apr;23(4):493-500
pubmed: 28263307
Nature. 2006 Dec 7;444(7120):761-5
pubmed: 17151667
Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82
pubmed: 18000526
Nat Neurosci. 2017 Jan;20(1):10-15
pubmed: 27775720
Cancer Discov. 2013 May;3(5):512-9
pubmed: 23539269
Cancer Cell. 2017 May 8;31(5):635-652.e6
pubmed: 28434841
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Nat Genet. 2006 May;38(5):525-7
pubmed: 16642017
Neuro Oncol. 2017 Sep 1;19(9):1279-1280
pubmed: 28821206
Nat Rev Clin Oncol. 2012 May 29;9(7):400-13
pubmed: 22641364
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
Nat Med. 2017 Apr;23(4):483-492
pubmed: 28263309
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nat Genet. 2014 May;46(5):457-461
pubmed: 24705252
Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4453-8
pubmed: 21368213
J Comp Neurol. 2015 Feb 15;523(3):449-62
pubmed: 25307966
Nat Chem Biol. 2008 Jan;4(1):33-41
pubmed: 18026094
Nature. 2011 Oct 26;478(7370):483-9
pubmed: 22031440
J Med Chem. 2014 Oct 9;57(19):7900-15
pubmed: 25101911
PLoS One. 2017 Jun 5;12(6):e0178593
pubmed: 28582410
Nat Neurosci. 2013 Sep;16(9):1211-1218
pubmed: 23872599
PLoS One. 2013 Apr 30;8(4):e62721
pubmed: 23646137
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
J Neurooncol. 2017 Apr;132(2):323-331
pubmed: 28093680
Nat Genet. 2014 May;46(5):451-6
pubmed: 24705254
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Nat Rev Cancer. 2014 Oct;14(10):
pubmed: 25230881
Acta Neuropathol. 2015 May;129(5):669-78
pubmed: 25752754
J Bone Miner Metab. 2013 Jan;31(1):26-33
pubmed: 23011467
Nat Med. 2014 Dec;20(12):1394-6
pubmed: 25401693
Cancer Lett. 2017 Aug 1;400:110-116
pubmed: 28450157
Sci Transl Med. 2015 Sep 2;7(303):303ra137
pubmed: 26333933
Nat Genet. 2014 May;46(5):462-6
pubmed: 24705250
Hum Mutat. 2009 Mar;30(3):379-90
pubmed: 19085907
Cancer Res. 2014 Sep 1;74(17):4565-70
pubmed: 25136070
Biochim Biophys Acta. 2013 Oct;1829(10):1147-59
pubmed: 23948603
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Cancer Res. 2010 Mar 15;70(6):2548-57
pubmed: 20197468
Blood. 2017 Mar 30;129(13):1823-1830
pubmed: 28188131
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):409-18
pubmed: 19914855
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062
Neuro Oncol. 2017 Feb 1;19(2):153-161
pubmed: 27282398

Auteurs

Diana Carvalho (D)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Kathryn R Taylor (KR)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
3Stanford University School of Medicine, Stanford, 94305 CA USA.

Nagore Gene Olaciregui (NG)

Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.

Valeria Molinari (V)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Matthew Clarke (M)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Alan Mackay (A)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Ruth Ruddle (R)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Alan Henley (A)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Melanie Valenti (M)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Angela Hayes (A)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Alexis De Haven Brandon (AH)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Suzanne A Eccles (SA)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Florence Raynaud (F)

2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Aicha Boudhar (A)

5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.
6Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, OX3 7FZ UK.

Michelle Monje (M)

3Stanford University School of Medicine, Stanford, 94305 CA USA.

Sergey Popov (S)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
7Department of Cellular Pathology, University Hospital of Wales, Cardiff, CF14 4XW UK.

Andrew S Moore (AS)

8Diamantina Institute and Child Health Research Centre, The University of Queensland, Brisbane, QLD 4101 Australia.
Oncology Service, Queensland Children's Hospital, Brisbane, QLD 4029 Australia.

Jaume Mora (J)

Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.

Ofelia Cruz (O)

Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.

Mara Vinci (M)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.
10Bambino Gesù Children's Hospital, Rome, 00165 Roma RM Italy.

Paul E Brennan (PE)

5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.
6Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, OX3 7FZ UK.

Alex N Bullock (AN)

5Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK.

Angel Montero Carcaboso (AM)

Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain.

Chris Jones (C)

1Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK.
2Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH